Parkinson’s Drug Istradefylline Promising for Fragile X, Mouse Study Says – Fragile X News Today

Related Articles:

• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Neurological Mayhem by Dual Antioxidative and Anti-inflammatory Agents in Aged Parkinson’s Mice February 26, 2019 “No person was ever honored for what he received. Honor has been the reward for what he gave.” Calvin Coolidge “The most reliable way to predict the future is to create it.” Abraham Lincoln Introduction: Recently, Jeff Keegan asked me if I had seen the paper by Gil-Martínez et al., an established Parkinson’s research group in Spain (click here to…
• Monthly Research Review – November 2019 November 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Nourianz Approved in US as Add-on Therapy to Carbidopa/Levodopa to Treat Off Periods in Parkinson’s August 29, 2019 The U.S Food and Drug Administration (FDA) has approved Kyowa Kirin’s Nourianz (istradefylline) tablets as an add-on therapy to treat off periods in Parkinson’s disease patients on a carbidopa/levodopa regimen. Off periods — when the effects of a medication wear off before a new dose can be taken — are characterized by the re-emergence of Parkinson’s motor symptoms and are typically more…
• A new therapeutic strategy with istradefylline for postural deformities in Parkinson's disease. August 24, 2019 A new therapeutic strategy with istradefylline for postural deformities in Parkinson's disease. Neurol Neurochir Pol. 2019 Aug 23;: Authors: Fujioka S, Yoshida R, Nose K, Hayashi Y, Mishima T, Fukae J, Kitano K, Kikuchi H, Tsuboi Y Abstract AIM OF THE STUDY: Postural deformities are common in Parkinson's disease (PD) patients. Several treatment options have been reported, but responses to…
• Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. January 29, 2021 Related ArticlesIstradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Rev Neurother. 2021 Jan 28;: Authors: Jenner P, Mori A, Aradi SD, Hauser RA Abstract Introduction It is now accepted that Parkinson's disease (PD) is not simply a movement disorder due to dopaminergic dysfunction, and there is keen interest in developing non-dopaminergic approaches to…
• Nourianz Now Available in US as Add-on to Carbidopa/Levodopa to Treat Parkinson’s Off Periods October 17, 2019 Kyowa Kirin’s Nourianz (istradefylline) tablets are now available in the United States as an add-on treatment for off periods in Parkinson’s disease patients on a carbidopa/levodopa regimen. Off periods — when the effects of a medication wear off before a new dose can be taken — are characterized by the re-emergence of Parkinson’s motor symptoms and are typically more common as the disease…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• New medication, Istradefylline, gets approved for Parkinson’s disease September 4, 2019 New medication, Istradefylline, gets approved for Parkinson’s disease On August 27, 2019, pharmaceutical company Kyowa Kirin received FDA approval for Istradefylline, a new medication for Parkinson’s disease (PD) to be used as an add-on treatment to carbidopa/levodopa for those experiencing OFF episodes. (For more information on OFF periods in PD, please see this recent APDA webinar.) The medication, which will…
• Importance of Magnesium in the Brain and Magnesium Threonate is Neuroprotective in a Mouse Model of Parkinson’s March 5, 2020 “The world may be broken, but hope is not crazy.” John Green “Our eternal message of hope is that dawn will come.” Martin Luther King, Jr. Introduction:  Epidemiological studies show that magnesium deficiency is associated with a Parkinson’s like syndrome called Parkinson-Dementia Syndrome (PDC). PDC patients have progressive cognitive decline, parkinsonian, and the loss of the dopaminergic neurons in the substantia…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: A single-arm, open-label, prospective, multicenter study. May 2, 2019 Related ArticlesEfficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: A single-arm, open-label, prospective, multicenter study. Expert Opin Pharmacother. 2019 Apr 30;: Authors: Iijima M, Orimo S, Terashi H, Suzuki M, Hayashi A, Shimura H, Mitoma H, Kitagawa K, Okuma Y Abstract BACKGROUND: Gait disorders are common in Parkinson's disease patients who respond poorly to dopaminergic…
• The Neuraly trial November 5, 2019       This week a new clinical trial was registered which caught our attention here at the SoPD HQ. It is being sponsored by a small biotech called Neuraly and involves a drug called NLY01. NLY01 is a GLP-1R agonist – that is a molecule that binds to the Glucagon-like peptide-1 receptor and activates it. Other GLP-1R agonists include…
• Monthly Research Review – August 2019 August 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Parkinson's Disease News - Editor's Picks (Archive 2016.09) October 15, 2016 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed ‘The Terrorist Inside My Husband’s Brain’: Robin Williams’ Widow Details His Disease – Live ScienceLive Science'The Terrorist Inside My Husband's Brain': Robin Williams' Widow Details His DiseaseLive ScienceBut Robin Williams was not diagnosed with Lewy body disease…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Repurposing: From enlarged prostates to Parkinson’s September 18, 2019   This week exciting new research from a collaboration between Chinese researchers and scientists at the University of Iowa has pointed towards a clinically-available, generic drug that could be re-purposed for Parkinson’s. The researchers found a drug called Terazosin – which is used for the treatment of enlarged prostates and high blood pressure – can boost energy production in neurons,…
• FDA accepts Kyowa Hakko's refilling for PD drug istradefylline - The Pharma Letter April 5, 2019 FDA accepts Kyowa Hakko's refilling for PD drug istradefylline  The Pharma LetterThe US Food and Drug Administration has accepted for review the resubmitted New Drug Application (NDA) for istradefylline (KW-6002), an investigational ...
• The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. December 23, 2020 Related ArticlesThe challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020 Dec 15;:54-63 Authors: LeWitt PA, Aradi SD, Hauser RA, Rascol O Abstract Laboratory and clinical experience have pointed to the value of targeting motor pathways emerging from the striatum to treat problems arising in advanced Parkinson's disease (PD). These pathways are…